https://www.selleckchem.com/products/byl719.html
The virtual patients were up-titrated to their individual dose with two different titration rules. The last 2-week simulated continuous glucose monitoring data were used to calculate various outcome metrics for both basal insulin treatments, with primary outcome being the percent time in glucose target (70-140 mg/dL). The simulations show no statistically significant difference for Gla-300 vs. Deg-100 in the main endpoints. This work suggests comparable glucose control using either Gla-300 or Deg-100 and was used to guide the design of a
Like
Comment
Share
